diethoxy-(1-phenyl-1-3-butanedionato)titanium-(iv) and Ovarian-Neoplasms

diethoxy-(1-phenyl-1-3-butanedionato)titanium-(iv) has been researched along with Ovarian-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for diethoxy-(1-phenyl-1-3-butanedionato)titanium-(iv) and Ovarian-Neoplasms

ArticleYear
Active cytotoxic reagents based on non-metallocene non-diketonato well-defined C2-symmetrical titanium complexes of tetradentate bis(phenolato) ligands.
    Journal of the American Chemical Society, 2007, Oct-10, Volume: 129, Issue:40

    Topics: Antineoplastic Agents; Cell Line, Tumor; Crystallography, X-Ray; Diamines; Drug Screening Assays, Antitumor; Female; HT29 Cells; Humans; Ligands; Organometallic Compounds; Ovarian Neoplasms; Phenols; Titanium

2007
New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells.
    Cancer research, 1991, Jun-01, Volume: 51, Issue:11

    DNA protein cross-links (DPC), DNA interstrand cross-links (ISCL), and DNA single strand breaks following treatment of experimental ovarian tumor cells (O-342) with five new metal complexes (three platinum, one titanium, one ruthenium compounds) were investigated at 6, 24, and 48 h after drug exposure and compared with their in vitro growth inhibitory potential. cis-Diamminedichloroplatinum(II) (cisplatin, DDP) served as reference drug. The following new compounds were tested: 18-crown-6-tetracarboxybis-diammineplatinum(II) (CTDP), cis-aminotrismethylenephosphonato-diammineplatinum(II) (AMDP), cis-diamminecyclohexano-aminotrismethylenephosphonato-platin um(II) (DAMP), diethoxybis-(1-phenylbutane-1,3-dionato)-titanium(IV) (budotitane), and trans-indazolium-tetrachlorobisindazole-ruthenate(III) (IndCR). At equimolar concentrations DNA cross-linking activity of the platinum agents decreased in the order cisplatin, CTDP, AMDP, DAMP; this was paralleled by growth inhibition in a cell proliferation assay. CTDP-induced interstrand cross-linking occurred more slowly compared to cisplatin (DDP) (6 h: CTDP, 73 +/- 15 versus DDP, 365 +/- 72 rad equivalents), but reached a peak similar to cisplatin 24 h after exposure (CTDP, 317 +/- 68 versus DDP, 392 +/- 116 rad equivalents). At this time point in contrast to DDP no DNA protein cross-links were observed for CTDP (total cross-links: CTDP 310 +/- 71, DDP 1987 +/- 436 rad equivalents). Thus, at 24 h, CTDP was found to be distinctly less reactive to proteins than DDP, and it is suggested that CTDP might be similar in its toxicity pattern to the structurally related compound carboplatin which was also reported to be less reactive to protein than DDP. By 48 h, CTDP- and DDP-induced interstrand cross-links were 65 +/- 21 and 180 +/- 33 rad equivalents, respectively. Although at a lower level, by 24 h, AMDP showed a ratio of ISCL to total cross-links (179 +/- 39 versus 213 +/- 31 rad equivalents), which was comparable to CTDP. The second biphosphonate complex DAMP was the least active platinum compound in terms of DNA damage, effecting only 16 +/- 7 rad equivalents ISCL and 63 +/- 28 rad equivalents total cross-links; similar to DDP, DAMP displayed a higher DPC fraction at 24 h. The titanium complex diethoxybis-(1-phenylbutane-1,3-dionato)-tita-++ +nium(IV) showed dose-dependent inhibition of cell proliferation, while no significant DNA damage could be detected with the alkaline elution technique. These results, together wi

    Topics: Animals; Crown Ethers; DNA, Neoplasm; Drug Screening Assays, Antitumor; Ethers, Cyclic; Ethylnitrosourea; Female; Indazoles; Organometallic Compounds; Organophosphorus Compounds; Organoplatinum Compounds; Ovarian Neoplasms; Rats; Ruthenium; Titanium

1991
chemdatabank.com